• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. EUFLEXXA; 1%  SODIUM HYALURONATE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. EUFLEXXA; 1%  SODIUM HYALURONATE Back to Search Results
Catalog Number 6301182010
Device Problem Use of Device Problem (1670)
Patient Problem Heart Failure/Congestive Heart Failure (4446)
Event Type  Injury  
Event Description
Chf [cardiac failure congestive].Case narrative: (b)(6) is a serious spontaneous case received from a health professional via regulatory authority in the united states.This report concerns a female patient of unknown age who experienced congestive heart failure (chf) during treatment with euflexxa (sodium hyaluronate) solution for injection unknown concentration and dose, 1 syringe intra-articular into the right knee for 3 weeks, for unknown indication from an unknown start date to an unknown stop date.The reporter stated that the patient's daughter said that her mother was currently in the hospital due to congestive heart failure (chf).The patient was hospitalized on an unspecified date 2022 due to chf.Action taken with euflexxa was unknown.At the time of the report,, the outcome of chf was not recovered.No concomitant medication was reported.All events in the case were reported as serious.Overall listedness (core label) is unlisted.Reporter causality: related.Company causality: not related.Other case numbers: internal # - others = mw5108905.4446: heart failure/congestive heart failure 2993: adverse event without identified device or use problem this ae occurred in united states and concerns the medical device euflexxa.Please report to your local health authority if required by local law.This ae is not reportable in eu because it does not meet the definition of a medical device incident according to the requirements of the medical device directive/ because it did not occur in a eu + efta country and did not result in a corrective action by the manufacturer.No corrective action was done by the manufacturer or requested by regulators.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
EUFLEXXA
Type of Device
1%  SODIUM HYALURONATE
Manufacturer (Section D)
BIO-TECHNOLOGY GENERAL (ISRAEL) LTD.
pob 571, be'er tuvia industria
l zone
kiryat malachi 83104 02
IS  8310402
MDR Report Key16551693
MDR Text Key311385618
Report Number0002244564-2022-00023
Device Sequence Number1
Product Code MOZ
Combination Product (y/n)Y
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Distributor
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 03/15/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Catalogue Number6301182010
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Event Location Other
Initial Date Manufacturer Received Not provided
Initial Date FDA Received03/16/2023
Type of Device Usage A
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Required Intervention;
Patient SexFemale
-
-